COPD is a pharmaceutical elective which cases Pulmonary Rehabilitation. COPD are items gotten from Lung Cancer that are implied to give additional medical advantages, notwithstanding the fundamental benefit found in COPD and Cardiovascular Diseases. Contingent upon the locale, items may profess to forestall interminable ailments, improve wellbeing, defer the maturing procedure, increment future, or bolster the structure or capacity of the Cardiovascular Diseases.

The COPD 2020 is an event that aims to explore the ways to innovate in the field of COPD and Cardiovascular Diseases, and to find new catalysts for better industrial development at Barcelona, Spain on September 30-October 01, 2020. The conference will serve as a platform to bring together leading Pulmonologists with different specialties such as Asthma and COPD, Pulmonary Hypertension etc. COPD 2020 will discuss on the topics such as Pathophysiology of COPD, Self-Management and Prevention of COPD, COPD and Cardiovascular Diseases, Pulmonary Rehabilitation, Lung Cancer, and COPD Therapeutics.

COPD 2020 supported by the organizing committee network of renowned scientific and professional expert such as Irine Pkhakadze, Kutaisi Akaki Tsereteli State University, Georgia, Xiaohong Zhou, Shanghai Medical University, Sweden it provided a platform for collaboration among colleagues, vendors, and academia to reveal new innovations, solutions, ideas, and emerging technologies in COPD & Pulmonary Rehabilitation.

According to a new report released by Transparency Market Research, The global COPD market ought to reach $336.1 billion by 2023 from $230.9 billion in 2018 at a compound annual rate of growth (CAGR) of seven.8%, from 2018 to 2023.